Srivastava R A, Baumann D, Schonfeld G
Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110 1093.
Eur J Biochem. 1993 Sep 1;216(2):527-38. doi: 10.1111/j.1432-1033.1993.tb18171.x.
Rats and mice are frequently used in studies of the regulation of lipoprotein metabolism. Although the species are closely related, they differ dramatically in the responses of their lipoproteins to estrogen administration. In rats, estrogens produce profound decreases in the levels of all plasma lipoproteins and this is attributed largely to estrogen-induced increases of hepatic low-density lipoprotein receptor (LDL-receptor) activity. Estrogens affect mouse plasma lipoproteins to a much lesser extent. Therefore, one of our aims was to compare the regulation of LDL-receptor gene expression in rats and mice at several potential loci of regulation. To assess the specificity of the estrogen effect, we also compared the responses of apolipoprotein AI (apoAI), apolipoprotein B (apoB), and beta-actin to the response of the LDL-receptor. In male Sprague Dawley rats given 17 beta-estradiol or 17 alpha-ethinyl estradiol at supraphysiological doses of 5 micrograms/g body mass/day, plasma total cholesterol and triacylglycerols fell to approximately 5% and approximately 50%, and, plasma apoAI and apoB fell to approximately 12% and approximately 16% of controls, respectively. By contrast, in male C3H/HeJ mice the above parameters dropped only to approximately 65% of controls and apoB concentrations rose to approximately 200% of controls. In rats, relative rates of LDL-receptor mRNA transcription (nuclear 'run-off' assay) and total hepatic, nuclear and polysomal LDL-receptor mRNA levels (RNase protection assay) increased by 1.5-2-fold, while synthesis of LDL-receptor protein on hepatic polysomes (in a wheat-germ translation system) increased 8-fold and LDL-receptor protein mass in hepatic plasma membranes increased 10-fold (by immunoblotting). In mouse liver, too, LDL-receptor mRNA levels increased 1.5-fold and the LDL-receptor mRNA transcription start sites in rat and mouse were found to be the same, but mouse LDL-receptor protein mass did not change, i.e. LDL-receptors of mice were similar to rat with respect to transcriptional regulation, but differed in their post-transcriptional control mechanisms. In rats, estrogen administration increased apoAI mRNA transcription rates 1.6-fold and also apoAI mRNA levels in total liver homogenates, nuclei and polysomes, (2-fold for each) consistent with transcriptional regulation. However, apoAI synthesis on total RNA increased less than apoAI mRNA, indicating that apoAI translational control mechanisms, at least in part, also regulate hepatic rates of apoAI production. ApoB mRNA transcription rates and levels showed small increases following estrogen administration. Hepatic beta-actin mRNA transcription and levels did not change.(ABSTRACT TRUNCATED AT 400 WORDS)
大鼠和小鼠常用于脂蛋白代谢调节的研究。尽管这两个物种亲缘关系密切,但它们的脂蛋白对雌激素给药的反应却有显著差异。在大鼠中,雌激素会使所有血浆脂蛋白水平大幅降低,这主要归因于雌激素诱导的肝脏低密度脂蛋白受体(LDL受体)活性增加。雌激素对小鼠血浆脂蛋白的影响要小得多。因此,我们的目标之一是在几个潜在的调节位点比较大鼠和小鼠中LDL受体基因表达的调节情况。为了评估雌激素作用的特异性,我们还比较了载脂蛋白AI(apoAI)、载脂蛋白B(apoB)和β-肌动蛋白对LDL受体反应的情况。给雄性斯普拉格-道利大鼠按5微克/克体重/天的超生理剂量注射17β-雌二醇或17α-乙炔雌二醇后,血浆总胆固醇和三酰甘油分别降至对照水平的约5%和约50%,血浆apoAI和apoB分别降至对照水平的约12%和约16%。相比之下,在雄性C3H/HeJ小鼠中,上述参数仅降至对照水平的约65%,而apoB浓度升至对照水平的约200%。在大鼠中,LDL受体mRNA转录的相对速率(核“连续转录”测定)以及肝脏总LDL受体mRNA水平、核LDL受体mRNA水平和多核糖体LDL受体mRNA水平(核糖核酸酶保护测定)增加了1.5至2倍,而肝脏多核糖体上LDL受体蛋白的合成(在麦胚翻译系统中)增加了8倍,肝细胞膜中LDL受体蛋白量增加了10倍(通过免疫印迹法)。在小鼠肝脏中,LDL受体mRNA水平也增加了1.5倍,并且发现大鼠和小鼠中LDL受体mRNA转录起始位点相同,但小鼠LDL受体蛋白量没有变化,即小鼠的LDL受体在转录调节方面与大鼠相似,但在转录后控制机制上有所不同。在大鼠中,给予雌激素使apoAI mRNA转录速率增加1.6倍,并且肝脏总匀浆、细胞核和多核糖体中的apoAI mRNA水平也增加(各增加2倍),这与转录调节一致。然而,总RNA上apoAI的合成增加量小于apoAI mRNA,这表明apoAI的翻译控制机制至少部分也调节肝脏中apoAI的产生速率。给予雌激素后,apoB mRNA转录速率和水平略有增加。肝脏β-肌动蛋白mRNA转录和水平没有变化。(摘要截断于400字)